Methods of using proteinacious channels to identify pharmaceutical treatments and risks, and treatments resulting therefrom
Methods and therapeutic strategies utilizing proteinacious channels in lipid membranes of mammalian cells. The methods entail administering a pharmaceutical to a lipid membrane of a mammalian cell, and then determining the effect of the pharmaceutical on the electrophysiology of at least one proteinacious channel of the lipid membrane, wherein the proteinacious channel is a Kv7 potassium channel and/or a L-type calcium channel of an airway smooth muscle cell (ASMC). The method can be used to identify pharmaceuticals that may be used to treat asthmatic and other bronchospastic conditions that can lead to airway obstruction, or to perform drug screening to assess potential risk of pharmaceuticals.
1. A method utilizing proteinacious channels in a lipid membrane of a mammalian cell, the method comprising:
administering a pharmaceutical to a lipid membrane of a mammalian cell;
measuring an electrical activity across the lipid membrane to determine an effect of the pharmaceutical on the electrophysiology of Kv7 potassium channels of the lipid membrane of an airway smooth muscle cell; and then
identifying pharmaceutical treatments for airway medical conditions or risks of the pharmaceutical based on the electrical activity caused by the pharmaceutical, wherein the medical conditions are affected by the electrophysiology of the Kv7 potassium channels.
2. The method according to claim 1 , wherein the step of measuring the electrical activity determines the effect of the pharmaceutical on currents generated by the Kv7 potassium channels.
3. The method according to claim 1 , further comprising administering the pharmaceutical to a living body if the effect of the pharmaceutical is to activate the Kv7 potassium channels during the step of measuring the electrical activity.
4. The method according to claim 1 , wherein the administering step comprises administering the pharmaceutical to cultured cells engineered to express large numbers of Kv7 potassium channels.
5. The method according to claim 1 , wherein the airway smooth muscle cell is in a wall of a bronchiole of a lung.
6. A method utilizing proteinacious channels in a lipid membrane of a mammalian cell, the method comprising:
administering a pharmaceutical to a lipid membrane of a mammalian cell; and then
determining the effect of the pharmaceutical on the electrophysiology of Kv7 potassium channels of the lipid membrane of an airway smooth muscle cell, wherein the method is performed to identify pharmaceuticals for treating airway conditions.
7. The method according to claim 6 , further comprising administering the pharmaceutical to a living body to treat a bronchospastic condition if the effect of the pharmaceutical is to activate the Kv7 potassium channels during the determining step.
8. The method according to claim 7 , wherein the bronchospastic condition is an asthmatic condition.
9. The method according to claim 1 , wherein the method is a drug screening procedure to assess potential risks of the pharmaceutical.
10. The method according to claim 9 , wherein the determining step comprises determining the effect of the pharmaceutical on currents generated by the Kv7 potassium channels.
11. The method according to claim 9 , further comprising administering the pharmaceutical to a living body if the effect of the pharmaceutical is to activate or inhibit the Kv7 potassium channels during the step of measuring the electrical activity.
12. A method utilizing proteinacious channels in a lipid membrane of a mammalian cell, the method comprising:
administering a pharmaceutical to a lipid membrane of a mammalian cell; and then
determining the effect of the pharmaceutical on the electrophysiology of Kv7 potassium channels of the lipid membrane of an airway smooth muscle cell, wherein the pharmaceutical is a COX-2 inhibitor.
13. The method according to claim 1 , wherein the pharmaceutical is a celecoxib analog.
14. The method according to claim 1 , wherein the pharmaceutical is not a COX-2 inhibitor.
15. The method according to claim 2 , wherein the Kv7 potassium channels are KCNQ4 and/or KCNQ5.
16. The method according to claim 4 , wherein the Kv7 potassium channels are KCNQ4 and/or KCNQ5.